YD Bio Limited (YDES)
NASDAQ: YDES · Real-Time Price · USD
13.91
+1.13 (8.89%)
At close: Dec 5, 2025, 4:00 PM EST
14.18
+0.28 (1.98%)
After-hours: Dec 5, 2025, 7:47 PM EST
YD Bio Revenue
In the year 2024, YD Bio had annual revenue of $510.36K with 45.76% growth. YD Bio had revenue of $142.69K in the quarter ending December 31, 2024, with 95.63% growth.
Revenue (ttm)
$510.36K
Revenue Growth
+45.76%
P/S Ratio
27.38
Revenue / Employee
n/a
Employees
n/a
Market Cap
977.80M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 510.36K | 160.23K | 45.76% |
| Dec 31, 2023 | 350.13K | -13.99K | -3.84% |
| Dec 31, 2022 | 364.12K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionYDES News
- 3 days ago - YD Bio Limited Expands OkaiDx™ Testing Portfolio to Pancreatic and Colorectal Cancer Detection Across the U.S. and Provides Clinical Research Update on Pancreatic Cancer Early Detection - GlobeNewsWire
- 11 days ago - YD Bio Limited Announces U.S. Ophthalmology Market Entry, Advances Across Diagnostics and LSC Exosome Therapeutics - GlobeNewsWire
- 4 weeks ago - YD Bio and EG BioMed Expand U.S. Access to OkaiDx™, a cfDNA‑Methylation Blood Test for Post‑Treatment Breast Cancer Monitoring - GlobeNewsWire
- 6 weeks ago - YD Bio Ltd. Rings Nasdaq Opening Bell to Celebrate Listing under Ticker YDES - GlobeNewsWire
- 2 months ago - YD Bio Business Partner EG Biomed Achieves CAP Accreditation, Advancing U.S. Clinical Testing Capabilities - GlobeNewsWire
- 2 months ago - YD Bio Limited Reports Unaudited Half Year 2025 Financial Results - GlobeNewsWire
- 3 months ago - YD Bio Limited Announces Closing of Business Combination and Listing on the Nasdaq Global Market - PRNewsWire